Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4701-4708

  Ong, Kwok Leung ^a,b   Rye, Kerry Anne ^a,b,d   O'Connell, Rachel ^c   Jenkins, Alicia J ^c,d   Brown, Chris ^c   Xu, Aimin ^e   Sullivan, David R ^f   Barter, Philip J ^a,b   Keech, Anthony C ^c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A2; CHOLESTEROL; CREATININE; FATTY ACID BINDING PROTEIN 4; FENOFIBRATE; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 21; GLYCOSYLATED HEMOGLOBIN; HOMOCYSTEINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATTY ACID BINDING PROTEIN 4 BLOOD LEVEL; FEMALE; FIBROBLAST GROWTH FACTOR 21 BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; RETINOL BINDING PROTEIN 4 BLOOD LEVEL;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DOUBLE-BLIND METHOD; FEMALE; FENOFIBRATE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; RETINOL-BINDING PROTEINS, PLASMA; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84870750824     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2267     Document Type: Article

References (29)

1. McKeage K, Keating GM 2011 Fenofibrate: a review of its use in dyslipidaemia. Drugs 71:1917-1946
2. Willson TM, Brown PJ, Sternbach DD, Henke BR 2000 The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550 (Pubitemid 30127149)
3. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet [Erratum (2006) 36:1420] 366:1849-1861
4. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG; FIELD study investigators 2007 Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:1687-1697 (Pubitemid 350100775)
5. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD study investigators 2009 Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373:1780-1788
6. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB 2005 FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627-1635 (Pubitemid 40814671)
7. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E 2007 Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426-437 (Pubitemid 46825495)
8. Nishimura T, Nakatake Y, Konishi M, Itoh N 2000 Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203-206 (Pubitemid 30349198)
9. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA 2007 Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425 (Pubitemid 46825496)
10. Lundåsen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, Rudling M 2007 PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360:437-440 (Pubitemid 47039157)
11. Rosell M, Hondares E, Iwamoto S, Gonzalez FJ, Wabitsch M, Staels B, Olmos Y, Monsalve M, Giralt M, Iglesias R, Villarroya F 2012 Peroxisome proliferator-activated receptors-α and -γ, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue. Endocrinology 153:1162-1173
12. Spiegelman BM 1998 PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514 (Pubitemid 28160438)
13. Xu A, Vanhoutte PM 2012 Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol 302:H1231-H1240
14. Chen C, Cheung BM, Tso AW, Wang Y, Law LS, Ong KL, Wat NM, Xu A, Lam KS 2011 High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 34:2113-2115
15. Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M 2008 The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab 8:169-174
16. Kotnik P, Fischer-Posovszky P, Wabitsch M 2011 RBP4: a controversial adipokine. Eur J Endocrinol 165:703-711
17. Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ; FIELD study investigators 2009 Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 29:950-955
18. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, George J 2009 Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 49:1926-1934
19. Haluzík MM, Anderlová K, Dolezalová R, Adamíková A, Haluzíková D, Housová J, Svacina S, Haluzík M 2009 Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol Res 58:93-99
20. Wu H, Wei L, Bao Y, Lu J, Huang P, Liu Y, Jia W, Xiang K 2009 Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. Am J Physiol Endocrinol Metab 296:E628-E634
21. Christou GA, Tellis CC, Elisaf MS, Tselepis AD, Kiortsis DN 2012 The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment. Angiology 63:67-75
22. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D 2009 Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32:1542-1546
23. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M 2009 Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71:369-375
24. Wallace TM, Levy JC, Matthews DR 2004 Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495 (Pubitemid 38680001)
25. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D 2007 Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab 92:1971-1974 (Pubitemid 46997219)
26. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators 2011 Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 54:280-290
27. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, Inoue K, Fushiki T, Itoh N 2009 Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150:4625-4633
28. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E 2009 Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150:4931-4940
29. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA 2012 Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 148:556-567